Dosing has commenced in HMNC Brain Health and Develco Pharma's Phase 2 oral prolonged-release Ketamine (KET01) Study The trial will assess the efficacy, safety, and tolerability of add-on treatment
Dosing has commenced in HMNC Brain Health and Develco Pharma’s Phase 2 oral prolonged-release Ketamine (KET01) Study The trial will assess the efficacy,.
The First Art Newspaper on the Net., art daily,art news,artdaily, daily art, art, art newspaper, Museums, Exhibits, Artists, Milestones, Digital Art, Architecture, Photography, Photographers, Special Photos, Special Reports, Featured Stories, Auctions, Art Fairs, Anecdotes, Art Quiz, Education, Mythology, 360 Images, 3D Images, Last Week,, , , , ,